František Nehaj, Marianna Kubašková, Michal Mokáň ml., Miroslava Dobrotová, František Kovář, Marián Mokáň, Peter Galajda
Nowadays, direct oral anticoagulants are very often used drugs in the prevention of cerebral stroke and systemic embolization
not only in patients with non-valvular atrial fibrillation (NVAF). Idarucizumab is a specific antidote for dabigatran
etexilate– which is a drug used for anticoagulation, that prevent blood clots from forming by blocking a certain
substance – thrombin. It is a monoclonal antibody designed for the reversal of anticoagulant effects of dabigatran. We
present a case report of 67-years-old woman with major unlocalized bleeding from lower gastrointestinal tract. The patient
with NVAF was taking dabigatran, in whom idarucizumab administered because of major bleeding complication.